Targeting the interleukin-33 (IL-33) pathway could soon expand biologic therapy to the vast majority of chronic obstructive pulmonary disease (COPD) patients, fundamentally shifting care beyond the restrictive biomarker criteria that currently leave most individuals without targeted options. According to expert analysis presented by Dr. Polverino, while existing approved biologics cater to a subset of type 2-high patients representing roughly 20 percent of the COPD population, IL-33 is broadly elevated in both the blood and lungs of most individuals living with the disease.
Under current eosinophil-based guidelines, patients without elevated eosinophil counts lack access to biologic interventions. Because IL-33 signaling extends well beyond type 2 inflammation, therapies inhibiting this pathway could reach patients across the entire eosinophil spectrum. Polverino highlighted recent successful clinical trial results from studies that enrolled participants regardless of blood eosinophil levels, characterizing the ability to treat patients independently of eosinophilia as the central therapeutic breakthrough offered by the IL-33 pathway.
Despite this momentum, crucial mechanistic questions surrounding IL-33 biology must be answered before such therapies become a standard component of routine clinical practice. In vitro and ex vivo research using primary bronchial epithelial cells shows that the cytokine exists in two distinct forms with complementary roles in disease pathology. The reduced form primarily triggers inflammation and recruits inflammatory cells, whereas the oxidized form predominantly drives mucus plugging in the airways.
A significant hurdle remains in understanding how investigational therapies interact with both biological states. Because the reduced form can convert rapidly into the oxidized state, existing data have not yet determined whether specific agents preferentially target one form over the other. Polverino emphasized that future clinical research must demonstrate effective neutralization of both forms to optimize therapeutic outcomes and successfully curb both airway inflammation and mucus obstruction.
Original Source: https://www.hcplive.com/view/targeting-il-33-copd-who-benefits-what-remains-unknown-
Category:
Tags:
Publish Date: 2026-11-08 03:14:00
